Skip to main content

Table 3 Cardiovascular adverse events in participants ≥60 years of age with a cardiovascular medical history

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

CV AEs, n (%) Quarterly fremanezumab Monthly fremanezumab Placebo
(CM/EM: 675 mg/PBO/PBO) (EM: 225/225/225 mg) (CM: 675/225/225 mg)
Participants with CV medical history (n = 30) (n = 6) (n = 14) (n = 23)
  ≥1 CV AE 1 (3) 0 2 (14) 1 (4)
AEs with incidence ≥1 participant in any treatment/dose group
 Palpitations 0 0 1 (7) 1 (4)
 Hypertensive crisis 0 0 1 (7) 0
 Supraventricular tachycardia 1 (3) 0 0 0
Participants without CV medical history (n = 44) (n = 40) (n = 32) (n = 57)
  ≥1 CV AE 0 0 2 (6) 0
AEs with incidence ≥1 participant in any treatment/dose group
 Hot flush 0 0 1 (3) 0
 Hypertension 0 0 1 (3) 0
  1. CM, chronic migraine; EM, episodic migraine; PBO, placebo; CV, cardiovascular; AE, adverse event